What Is an Antibody-Drug Conjugate (ADC)? An Investor's Primer

The Idea: A Guided Missile for Cancer

An antibody-drug conjugate (ADC) is a cancer therapy designed to deliver a potent toxin selectively to tumor cells while sparing healthy tissue. The concept is often described as a "guided missile": an antibody finds the target, and a powerful payload destroys the cell once it arrives. ADCs have become one of the most active and valuable areas in oncology drug development.

The Three Components

Every ADC is defined by three parts, and the engineering of each determines whether it works:

1. The antibody. A monoclonal antibody that recognizes an antigen expressed on the surface of cancer cells. Target selection is critical — ideally the antigen is abundant on tumor cells and scarce on healthy ones.
2. The payload. A cytotoxic drug far too toxic to give on its own. Tethered to the antibody, it's delivered only where the antibody binds. Payload potency and class are key differentiators.
3. The linker. The chemical bridge connecting antibody and payload. The linker must be stable in the bloodstream (so the toxin isn't released prematurely) yet release the payload once inside the target cell. Linker chemistry is often where ADCs succeed or fail.

A subtle but important property is the drug-to-antibody ratio (DAR) — how many payload molecules each antibody carries — which affects potency and tolerability.

Why the Mechanism of Action Matters

The whole premise of an ADC is widening the therapeutic window: delivering more toxin to the tumor and less to healthy tissue than conventional chemotherapy. Whether a given ADC achieves that depends on the interplay of target, payload, linker, and DAR. Two ADCs against the same target can perform very differently based on this engineering — which is why understanding the mechanism of action is essential to evaluating one.

A notable feature of some ADCs is the bystander effect: payload released inside a target cell can diffuse to neighboring tumor cells, helping in tumors with uneven antigen expression. This can broaden efficacy but also influence the toxicity profile.

What Investors Should Watch

When evaluating an ADC program:

• Target validation. Is the antigen well-characterized, and how selective is it for tumor over healthy tissue? Off-target expression drives side effects.
• The payload and linker. Differentiated chemistry can mean better efficacy or tolerability than earlier-generation ADCs against the same target.
• The safety profile. ADCs have characteristic toxicities. Watch trial data for whether the payload's side effects are manageable.
• Competitive landscape. Popular targets attract many ADCs. Being first, best-in-class, or differentiated on a key axis matters in a crowded field — assess the competing programs across companies and indications.

Why ADCs Command Premium Valuations

ADCs have driven major partnerships and acquisitions, because a validated ADC platform can generate multiple products against different targets. For investors, a company with differentiated linker-payload technology may be valued not just on its lead asset but on the platform's potential to spawn a pipeline — a dynamic that shows up in licensing deals and valuation.

Applying It

ADCs sit at the intersection of antibody engineering and medicinal chemistry, and the details — target, payload, linker, DAR — determine success. When you assess an ADC company, look past "it's an ADC for [target]" to the engineering that differentiates it and the clinical data that validate the window between efficacy and toxicity.

Track ADC programs' clinical readouts on the Phase 3 calendar and FDA decisions, and review each company's modality and pipeline on its company page. In oncology, the ADC is only as good as the engineering behind the guided missile.